FDA ex­plains why it de­nied about 60% of non-on­col­o­gy break­through ther­a­py re­quests from 2017 to 2019

The FDA is of­fer­ing a look in­to why it de­nied about 60% of all break­through ther­a­py des­ig­na­tion re­quests it re­ceived from the bio­phar­ma in­dus­try …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.